Novo Nordisk A/S (NYSE:NVO) Receives $56.07 Consensus Price Target from Analysts

Shares of Novo Nordisk A/S (NYSE:NVO) have received a consensus rating of “Hold” from the twenty-one ratings firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $56.0714.

NVO has been the topic of several recent analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 3rd. Citigroup started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 27th. They issued a “neutral” rating on the stock. The Goldman Sachs Group reiterated a “buy” rating on shares of Novo Nordisk A/S in a report on Thursday, January 22nd. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Finally, Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, February 9th.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $49.59 on Thursday. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $93.80. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The firm’s fifty day moving average is $53.74 and its 200 day moving average is $53.22. The company has a market cap of $221.43 billion, a price-to-earnings ratio of 14.29 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is 23.63%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Berenberg maintained its Buy rating on Novo Nordisk, reinforcing investor confidence in the company’s growth outlook and valuation support from a respected European bank. Berenberg Bank Sticks to Their Buy Rating for Novo Nordisk (NVO)
• Positive Sentiment: IQVIA data show Wegovy oral-pill prescriptions hitting ~38,220 in week five post-launch, signaling strong early uptake for the new oral formulation and supporting near-term revenue momentum. Novo’s Wegovy pill tracks over 38,000 prescriptions in fifth week
• Positive Sentiment: Company update: Novo completed a Phase 3 study of oral semaglutide in youth diabetes care — a potential label expansion that could broaden the drug’s addressable market if approved. Novo Nordisk Advances Oral Semaglutide Into Youth Diabetes Care
• Positive Sentiment: Legal/market protection: U.S. officials may act against Hims after its attempted sale of a compounded Wegovy copy, which could help defend Novo’s IP and commercial position. US could take action including fines against Hims after brief Wegovy copy launch
• Positive Sentiment: Product strategy: Novo plans to introduce Wegovy in vial presentations (and other device formats), a move to improve access, pricing flexibility and supply resiliency amid competition. Novo Nordisk plans Wegovy vials amid obesity-drug competition
• Positive Sentiment: Usage trend: A study finds many Wegovy pill users are new to GLP‑1s, suggesting the product is bringing first‑time patients into the class and expanding market demand. Many users of Novo Nordisk Wegovy pill new to GLP-1s – study
• Neutral Sentiment: Company expansion: Coverage on Novo’s broader global healthcare initiatives highlights long‑term growth avenues but is less likely to move near‑term sentiment. How Is Novo Nordisk (NYSE:NVO) Expanding Its Global Healthcare Reach?
• Neutral Sentiment: Industry context: A CNBC piece on pharma’s “reset” around pricing and pipelines frames regulatory and pricing headwinds that apply across the sector. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Competitive landscape: Analysis comparing Eli Lilly and Novo Nordisk underscores intense competition in a rapidly growing weight‑loss market; investors should watch share trends and margin pressure. Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market
• Negative Sentiment: Regulatory/legal risk: Coverage about FDA warnings and potential lawsuits tied to Wegovy highlights an ongoing downside risk to valuation if safety signals or litigation escalate. FDA Wegovy Warning And Lawsuits Test Novo Nordisk Valuation Story

Institutional Trading of Novo Nordisk A/S

A number of institutional investors have recently added to or reduced their stakes in NVO. Revolve Wealth Partners LLC grew its position in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares during the period. AQR Capital Management LLC raised its stake in Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after acquiring an additional 10,758 shares during the period. Sivia Capital Partners LLC raised its holdings in shares of Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after buying an additional 1,587 shares during the last quarter. CWM LLC boosted its holdings in shares of Novo Nordisk A/S by 37.1% in the second quarter. CWM LLC now owns 107,998 shares of the company’s stock valued at $7,454,000 after acquiring an additional 29,246 shares in the last quarter. Finally, Yousif Capital Management LLC boosted its holdings in Novo Nordisk A/S by 7.0% during the second quarter. Yousif Capital Management LLC now owns 38,849 shares of the company’s stock worth $2,681,000 after buying an additional 2,553 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.